Physician profile
Michel Jeannot
NPI 1700023330
$6,895.40
in general payments reported to CMS, 2019-2025
35 companies · $784 in 2025
The $784 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $628 · 2021: $1,188 · 2022: $1,730 · 2023: $1,614 · 2024: $323 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,621.70 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $879.89 | 2019-2025 | Ofev, Jascayd |
| Jazz Pharmaceuticals INC. | $696.35 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $691.78 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals Lp | $685.14 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $614.98 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $580.67 | 2019-2025 | Nucala, Trelegy Ellipta |
| Baxter Healthcare | $555.76 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Mylan Specialty L.P. | $295.30 | 2019-2024 | Yupelri |
| Genzyme Corporation | $287.74 | 2021-2025 | |
| Grifols USA, LLC | $285.47 | 2019-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $170.66 | 2021-2023 | Acthar |
| Advanced Respiratory, INC | $156.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.30 | 2022-2025 | Glassia |
| Sunovion Pharmaceuticals INC. | $93.37 | 2019-2021 | |
| Eisai INC. | $87.13 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $73.03 | 2025 | Lumryz |
| Shire North American Group INC | $67.88 | 2019 | |
| Inspire Medical Systems, INC. | $61.33 | 2023-2025 | Inspire |
| Resmed Corp | $53.04 | 2022 | |
| Mallinckrodt Enterprises LLC | $45.90 | 2019 | |
| Verona Pharma, INC. | $43.82 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $43.08 | 2021-2023 | Belsomra |
| Electromed, INC. | $33.26 | 2022 | |
| Olympus America INC. | $29.92 | 2022 | |
| Axsome Therapeutics, INC. | $28.98 | 2023 | Sunosi |
| Ars Pharmaceuticals Operations, INC. | $27.54 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $26.88 | 2021 | |
| Abbvie INC. | $25.46 | 2024 | |
| Ani Pharmaceuticals, INC. | $22.91 | 2025 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $20.04 | 2022 | |
| Genentech USA, INC. | $19.04 | 2019 | |
| Amgen INC. | $18.18 | 2022 | |
| Pulmonx Corporation | $17.89 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Viatris Specialty LLC | $16.03 | 2025 | Yupelri |
| Circassia INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Jeannot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.